Jing Feng, Jiang Lingyun, Cao Yuling, Hu Yan
Fudan University School of Nursing, Shanghai, China and Fudan University Centre for Evidence-Based Nursing: A Joanna Briggs Institute Centre of Excellence, 305 Fenglin Rd, Shanghai, 200032, China.
Support Care Cancer. 2025 Jan 27;33(2):124. doi: 10.1007/s00520-025-09183-5.
Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are the most common adverse effects experienced by breast cancer patients. This scoping review aimed to systematically synthesize the predictors/risk factors and outcomes of AIMSS in patients with early-stage breast cancer.
A systematic search was conducted in PubMed, Web of Science, EMBASE, CINAHL, and the China National Knowledge Internet (CNKI) from inception to December 2024 following the scoping review framework proposed by Arksey and O'Malley (2005).
A total of 5,008 studies were identified, and 98 were included in this review. The risk factors for AIMSS included psychosocial and demographic factors (e.g., age, BMI, menstrual status, and anxiety), clinical factors (e.g., history of chemotherapy, preexisting pain, and musculoskeletal diseases) and gene polymorphisms (e.g., ESR1, OPG, RANKL, TCL1A, and CYP19A1). The outcomes of AIMSS encompassed physical, psychological, behavioral, and survival-related impacts.
This scoping review synthesized the available evidence on predictors, risk factors, and outcomes of AIMSS, providing a foundation for developing risk prediction models and enhancing symptom management strategies.
芳香化酶抑制剂相关肌肉骨骼症状（AIMSS）是乳腺癌患者最常见的不良反应。本范围综述旨在系统总结早期乳腺癌患者AIMSS的预测因素/风险因素及结局。
按照Arksey和O'Malley（2005年）提出的范围综述框架，于2024年12月前在PubMed、科学网、EMBASE、CINAHL和中国知网（CNKI）中进行了系统检索。
共识别出5008项研究，本综述纳入了98项。AIMSS的风险因素包括心理社会和人口统计学因素（如年龄、体重指数、月经状况和焦虑）、临床因素（如化疗史、既往疼痛和肌肉骨骼疾病）以及基因多态性（如ESR1、OPG、RANKL、TCL1A和CYP19A1）。AIMSS的结局包括身体、心理、行为和生存相关影响。
本范围综述综合了关于AIMSS预测因素、风险因素和结局的现有证据，为开发风险预测模型和加强症状管理策略奠定了基础。
